CD163 and neoplasm: In another study of the PROMIX trial, a decrease to low levels (<10%) of FOXP3+ T-lymphocytes in biopsies taken after cycle 2 of NAC was significantly associated with an improved DFS, whereas concentration changes of CD163 macrophages during NAC were unrelated to survival or tumor response [48].